Bevacizumab for Non-Ocular Indications — CPB 0685 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0685 governing bevacizumab coverage for non-ocular indications, effective January 5, 2026. Billing teams need to review precertification requirements across seven bevacizumab products and update charge capture for J9035, Q5107, Q5118, Q5126, and Q5129 before submitting claims.

Aetna's bevacizumab coverage policy under CPB 0685 Aetna system now covers a wider set of oncology indications—but with tighter administrative controls. The update adds biosimilar-specific HCPCS codes, extends medical necessity criteria across multiple tumor types, and activates a site-of-care utilization management layer for all seven covered bevacizumab products. If your practice infuses bevacizumab for any oncology indication and bills Aetna commercial plans, this change touches your prior authorization workflow, your site-of-service documentation, and your HCPCS code selection on every claim.

Quick-Reference Table

Field	Detail
Payer	Aetna, a CVS Health company
Policy	Bevacizumab for Non-Ocular Indications
Policy Code	CPB 0685
Change Type	Modified
Effective Date	January 5, 2026
Impact Level	High
Specialties Affected	Oncology, Neuro-oncology, Gynecologic Oncology, GI Oncology, Thoracic Oncology, Infusion Centers
Key Action	Verify precertification is in place for all seven bevacizumab products and confirm site-of-care compliance before submitting claims

Aetna Bevacizumab Coverage Criteria and Medical Necessity Requirements 2026

Aetna considers bevacizumab medically necessary for a defined list of non-ocular oncology indications. Every indication has specific clinical conditions attached. "Bevacizumab for cancer" is not enough to clear prior authorization—the combination regimen, line of therapy, and sometimes molecular subtype all factor into the approval decision.

Precertification is required for all oncology indications. This applies to all seven products: bevacizumab (Avastin), bevacizumab-maly (Alymsys), bevacizumab-tnjn (Avzivi), bevacizumab-nwgd (Jobevne), bevacizumab-awwb (Mvasi), bevacizumab-adcd (Vegzelma), and bevacizumab-bvzr (Zirabev). Call (866) 752-7021 or fax (888) 267-3277 for precertification. Submit Statement of Medical Necessity forms through Aetna's Specialty Pharmacy Precertification portal.

The coverage policy also activates a site-of-care utilization management layer, effective January 1, 2026. This means Aetna will review where the infusion happens—not just whether it's medically necessary. Infusion centers billed under outpatient hospital codes face a different review pathway than office-based or home infusion settings. If your site-of-service doesn't match Aetna's preferred setting for specialty drug infusions, expect prior auth friction or outright denial.

This policy applies to commercial medical plans only. For Medicare criteria, see Aetna's Medicare Part B pathway.

Covered Oncology Indications: What Aetna Requires

The medical necessity bar varies significantly by tumor type. Here's what the policy specifies for each covered indication:

Ampullary Adenocarcinoma: Covered for intestinal-type ampullary adenocarcinoma that is progressive, unresectable, or metastatic.

CNS Cancers: Covered across 12 subtypes, including glioblastoma, diffuse high-grade gliomas, IDH mutant astrocytoma (WHO Grade 2, 3, or 4), oligodendroglioma (WHO Grade 2 or 3), medulloblastoma, primary CNS lymphoma, meningiomas, limited and extensive brain metastases, metastatic spine tumors, and primary spinal cord tumors. Intracranial and spinal ependymoma is covered but subependymoma is specifically excluded.

Cervical Cancer: Covered for persistent, recurrent, or metastatic disease.

Colorectal Cancer: Covered, including appendiceal adenocarcinoma and anal adenocarcinoma.

Hepatocellular Carcinoma: Covered in two scenarios. First, as initial treatment for unresectable or extrahepatic/metastatic disease in combination with atezolizumab (J9022). Second, as adjuvant treatment for operable disease in members at high risk of recurrence, again in combination with atezolizumab.

Mesothelioma: The criteria here are more layered. For pleural, peritoneal, pericardial, or tunica vaginalis testis mesothelioma, bevacizumab is covered as first-line therapy in combination with pemetrexed and cisplatin or carboplatin, followed by single-agent maintenance bevacizumab. It's also covered as subsequent therapy if immunotherapy was administered first-line. For peritoneal, pericardial, or tunica vaginalis testis mesothelioma specifically, bevacizumab plus atezolizumab is covered as subsequent therapy.

Non-Small Cell Lung Cancer (NSCLC) and other indications are addressed in the full policy but were truncated in the summary provided. Review the complete CPB 0685 document at Aetna's site before assuming coverage for any indication not listed above.

Aetna Bevacizumab Exclusions and Non-Covered Indications

The policy explicitly excludes subependymoma from the ependymoma coverage criteria. This is a specific carve-out—don't assume all ependymoma subtypes are covered.

The site-of-care policy adds a functional exclusion for certain infusion settings. Even when the indication is covered and prior auth is obtained, reimbursement can be denied if the infusion occurs at a site Aetna deems inappropriate under its utilization management policy for specialty drug infusions. That policy took effect January 1, 2026—the same effective date window as this CPB update.

The combination therapy requirements create another soft exclusion. For hepatocellular carcinoma, bevacizumab is only covered when paired with atezolizumab. Monotherapy for HCC is not covered under this policy. For mesothelioma first-line treatment, bevacizumab must be used in combination with pemetrexed plus either cisplatin or carboplatin. A claim without documentation of the full regimen is a claim denial waiting to happen.